Skip to main content

Table 1 Patient demographics and characteristics (ITT/safety population)

From: Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD

Parameter

GP MDI

Placebo

n = 62

Open-label tiotropium n = 62

18 μg

n = 64

9 μg

n = 64

4.6 μg

n = 62

2.4 μg

n = 64

1.2 μg

n = 57

0.6 μg

n = 59

Age, years

 Mean (SD)

61.6 (8.1)

60.6 (8.6)

60.8 (8.5)

60.2 (9.0)

61.6 (7.9)

60.3 (8.9)

61.3 (8.3)

60.7 (7.1)

Gender, n (%)

 Male

30 (46.9)

33 (51.6)

29 (46.8)

34 (53.1)

34 (59.6)

33 (55.9)

33 (53.2)

33 (53.2)

Race, n (%)

 White

58 (90.6)

58 (90.6)

57 (91.9)

58 (90.6)

53 (93.0)

55 (93.2)

56 (90.3)

57 (91.9)

Smoking status, n (%)

 Current

37 (57.8)

35 (54.7)

42 (67.7)

37 (57.8)

34 (59.6)

40 (67.8)

40 (64.5)

40 (64.5)

Duration of COPD, years

 Mean (SD)

7.2 (7.3)

6.0 (6.1)

8.0 (7.7)

6.6 (6.0)

6.7 (7.5)

7.5 (5.9)

8.3 (7.7)

7.2 (5.3)

Total CAT score

 Mean (SD)

20.0 (6.7)

20.7 (6.4)

19.5 (6.0)

19.8 (6.7)

20.5 (7.3)

19.9 (6.3)

20.3 (6.4)

20.5 (6.5)

n a

59

59

61

60

55

56

60

57

Mean FEV1, % predicted (SD)a

      

 Pre-bronchodilator

47.0 (11.9)

46.6 (13.0)

47.0 (11.3)

46.4 (11.7)

46.2 (10.6)

45.8 (11.9)

45.6 (11.6)

43.4 (10.9)

 Post-bronchodilator

55.2 (12.6)

53.7 (12.7)

54.2 (11.7)

55.1 (11.5)

54.5 (12.1)

52.9 (11.9)

53.1 (12.7)

52.5 (11.7)

 Change from pre- to post-bronchodilator

19.2 (16.9)

17.9 (17.2)

16.8 (14.4)

21.0 (15.8)

18.9 (15.3)

17.5 (16.4)

18.0 (16.6)

22.5 (15.2)b

Mean FEV1, L (SD)a

 Pre-bronchodilator

1.363 (0.392)

1.395 (0.490)

1.409 (0.432)

1.408 (0.466)

1.369 (0.366)

1.384 (0.456)

1.358 (0.417)

1.313 (0.416)

 Post-bronchodilator

1.603 (0.432)

1.601 (0.472)

1.632 (0.493)

1.670 (0.484)

1.609 (0.400)

1.602 (0.478)

1.587 (0.486)

1.585 (0.450)

 Change from pre- to post-bronchodilator

0.239 (0.199)

0.206 (0.203)

0.224 (0.183)

0.261 (0.170)

0.240 (0.181)

0.218 (0.225)

0.229 (0.216)

0.272 (0.162)b

  1. amITT population; b n = 55
  2. CAT COPD Assessment Test; COPD chronic obstructive pulmonary disease; FEV 1 forced expiratory volume in 1 s; GP glycopyrrolate; ITT intent-to-treat; MDI metered dose inhaler; mITT modified intent-to-treat; SD standard deviation